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Inhibitor Treatment in the Posttransplant Period
in Patients with Chronic Myelogenous Leukemia (CML)
Evgeny Klyuchnikov,1 Nicolaus Kro¨ger,1 Tim H. Brummendorf,2 Bettina Wiedemann,1
Axel Rolf Zander,1 Ulrike Bacher1Following the introduction of tyrosine kinase inhibitors (TKIs) in chronic myelogenous leukemia (CML),
allogeneic stem cell transplantation (SCT) took a shift toward high-risk patients. Considering the high relapse
rates posttransplant in these selected patients, several studies evaluated posttransplant use of the TKI
imatinib. Although the number of studies are still limited, and data have to be confirmed by additional studies,
safety of imatinib even within the first months after SCT seems to be acceptable. Imatinib was shown to be
effective in patients with molecular or hematologic relapse of chronic or accelerated phase posttransplant
(CP, AP), whereas outcomes in blast phase were more unfavorable. The compound further seemed beneficial
for prophylactic use in patients who achieved complete remission posttransplant. The combination of ima-
tinib with donor lymphocytes did not result in increased toxicity or graft-versus-host disease (GVHD). First
studies suggest that second-generation TKIs such as dasatinib or nilotinib aremanageable posttransplant with
acceptable toxicity as well. In conclusion, TKIs of the first- and second-generation are promising options for
the posttransplant period of patients with CML, but algorithms for dosage, intervals from SCT, duration of
application, and the combination with donor lymphocytes still have to be developed.
Biol Blood Marrow Transplant 16: 301-310 (2010)  2010 American Society for Blood and Marrow TransplantationKEY WORDS: Allogeneic stem cell transplantation (SCT), Chronic myelogenous leukemia (CML), Tyrosine
kinase inhibitors (TKIs), Imatinib, DasatinibINTRODUCTION
Following the introduction of the tyrosine kinase
inhibitor (TKI) imatinib (IM) as first-line strategy in
chronic myelogenous leukemia (CML) [1-3], the rates
of annual allogeneic stem cell transplantations (SCT)
in this entity were soon dropping worldwide. A Euro-
pean Blood and Marrow Transplant (EBMT) study
reported a decrease from 1396 in 1999 to a plateau
of800 annual transplantations in CMLper year since
2004 [4]. However, this decrease wasmost pronounced
in first chronic phase (CP), whereas allo-SCT still has
an important role for the treatment of high-risk
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failure of IM [5]. Thus, by now,.50% of transplanta-
tions in CML are performed in patients in advanced
disease [6]. Considering the high relapse rates up to
30% to 40% in patients with AP or BP after SCT
[4], posttransplant monitoring and prophylactic or
therapeutic strategies in this setting gain more and
more importance.
Whereas donor lymphocyte infusions (DLI) were
previously the only therapeutic option, the availabil-
ity of IM has broadened the spectrum of posttrans-
plant strategies in case of relapse of CML [7-11].
The largest study [9] included 128 patients, whereas
others reported on cohorts up to the size of 15 to
30 patients [7,8,10,11]. The median intervals from
SCT to the start of IM varied within these studies
from 4 weeks [10] to 54 months [11]. Dosages of
IM were also variable, ranging from 400 [9] to 1000
mg [7]. Further, 2 small series of patients with
CML or Philadelphia-positive acute lymphoblastic
leukemia (Phi1 ALL), who had been treated with
dasatinib in the posttransplant period, have been
reported. Thus, the introduction of second genera-
tion TKIs such as dasatinib and nilotinib[12,13] will
further expand posttransplant strategies.301
302 Biol Blood Marrow Transplant 16:301-310, 2010E. Klyuchnikov et al.Although the number of reported cases with
posttransplant TKI treatment are still limited, some
preliminary conclusions can be drawn. This review
focuses on the efficacy and safety of first- and second-
generation TKIs in the posttransplant period in
CML, and presents an overview on current strategies
concerning indication, dosage, and intervals fromSCT.
Efficacy of Posttransplant Imatinib
Hematologic relapse
Olavarria et al. [9] started IM in 128 patients with
different stages of CML who had hematologic relapse
posttransplant. Patients with relapse of CP received
400 mg daily, whereas those with advanced disease
(AP/BP) were treated with 600 mg doses. This
approach was highly effective in patients with relapse
of CP, who had a 100% overall survival (OS) after 2
years. In those patients with relapse of AP, the 2-year
OS was still favorable with 86%, whereas those in BP
had a 12% 2-year OS only. In more detail, cytogenetic
complete remission (CR) rates were 58% for CP, 48%
for AP, and 22% for BP.
Kantarjian et al. [7] used IM doses mostly of 600
mg daily (3 patients received a 1000-mg dose) in 28
adult patients with CP (n 5 5) or AP/BP (n 5 23)
with hematologic relapse. The overall hematologic
and cytogenetic response rates were 74% and 58%,
respectively. In patients with relapse of CP, a 100%
hematologic CR rate was achieved, whereas the rate
of hematologic CR was 83% in patients with AP and
43% in patients with BP. Cytogenetic response rates
were 63% for CP or AP and 43% for BP.
These data demonstrate the efficacy of posttrans-
plant IM for hematologic relapse of CP and AP,
whereas alternative strategies are needed for those
patients with relapse of BP.
Cytogenetic/molecular relapse
Hess et al. [14] analyzed outcomes in 37 patients
with cytogenetic or molecular relapse of CP. Patients
received 400 mg of IM, and in case of failure to achieve
a major molecular CR after 6 months of such therapy,
the IM dose was increased to 600-800 mg daily.
Within the initial 9-month period of study, 73% of
the 15 patients with cytogenetic relapse achieved cyto-
genetic CR, in 32% of patients being accompanied by
stable molecular remission. Those 18 patients with
molecular relapse had better outcomes, as all achieved
at least major molecular response, and 14 patients
(78%) achieved molecular CR. Also, they achieved
molecular CR after a median interval of 4 weeks in
contrast to 16 weeks in those with cytogenetic relapse.
In contrast, Palandri et al. [11] observed no differ-
ence whether patients received IM at cytogenetic/mo-
lecular or hematologic relapse posttransplant in 16
patients with different phases of disease. Four of 5patients with hematologic relapse achieved RT
(reverse transcription)-polymerase chain reaction
(PCR) negativity after a median of 7.5 months, which
was comparable to the 82% rate of molecular CRs in
those patients who received IM at cytogenetic/
molecular relapse after a median treatment duration
of 10.6 months. However, the small size of samples
has to be considered. It seems worthwhile to explore
the start of IM treatment in the posttransplant period
already at molecular relapse in larger cohorts.
Prophylactic use
Carpenter et al. [10] reported on the prophylactic
use of IM in patients with CML and Phi1 ALL. This
study included patients in CR as assessed by hemato-
logic parameters, cytogenetics, or interphase fluores-
cein in situ hybridization (FISH). Adult patients
received 400 mg daily, children had a 260 mg/m2
dose. Within a median follow-up of 1.4 years, 12 of
15 the Phi1 ALL patients and 5 of 7 the CML patients
maintained major molecular CR as assessed by quanti-
tative real-time PCR (qPCR), and there was a low he-
matologic relapse rate of 9% in the whole cohort [10].
Intervals from SCT to Start of Treatment
The intervals between SCT and posttransplant IM
administration were quite variable even within each
study. This has to be seen on the background of the
various comedications, unstable hematopoiesis, organ
toxicity because of pretransplant conditioning, and
finally infectious events, whichmakes a standardization
of the start of TKIs in the posttransplant period
difficult.
DeAngelo et al. [8] started IM with a median inter-
val from SCT of 21 months for patients in CP and 41
months for those in AP/BP (range: 1-60 months). This
time schedule was comparable to the study from Ola-
varria et al. [9], who started IM after a median interval
of 14 months from SCT (range: 1-161 months). Con-
sidering the time of relapse manifestation, IM was
started at a median interval of 5 months (range: 0-65
months). Longer intervals between SCT and IM
administration were chosen by Palandri et al. [11] as
the median interval to the start of IM was 54 months
(range: 7-160 months) and by Kantarjian et al. [7] as
patients received IM after a median of 41 months
(range: 3-140 months) from allo-SCT.
For prevention of relapse, Carpenter et al. [10]
started IM very early within the first month posttrans-
plant: The median interval was 28 days from SCT only
(21-39 days).
Tolerance of Posttransplant IM Treatment
Posttransplant IM treatment was generally well
tolerated. Thus, in the study by Olavarria et al. [9]
only 6 of 128 patients (5%) developed severe
Biol Blood Marrow Transplant 16:301-310, 2010 303Tyrosine Kindas Inhibitor Treatment for Patients with CMLpancytopenia when doses of 400-600mg IMdaily were
applied over a median duration of 9 months (range:
2-34 months). In no case IM had to be interrupted.
Kantarjian et al. [7] reported severe neutropenia in
43%, and severe thrombocytopenia in 27% of cases.
Liver dysfunction was seen in 18%, fluid retention in
10% of patients. Despite using IM doses up to 1000
mg daily, the authors did not find any increase in
adverse reactions.With respect to the elevation of liver
enzymes, inhibition of CYP3A4 by concomitant anti-
fungal triazole comedication may be relevant [10]. In
the study of DeAngelo et al. [8], posttransplant IM
was extremely well tolerated, and no patient had to dis-
continue therapy because of side effects. There was no
grade III/IV nonhematologic toxicity, and only
1 patient required dose reduction from 600 to 400
mg because of hematologic toxicity. Palandri et al.
[11] reported higher rates of severe complications, as
31% of patients developed grade III-neutropenia or
thrombocytopenia, and 13% of patients showed
musculoskeletal pain and periorbital edema.
Carpenter et al. [10] started preventive IM use
within the first month after SCT in 22 patients with
CML or Phi1 ALL. Most frequently, nausea, emesis,
and elevation of liver enzymes were reported to be
associated with IM prophylaxis. Adults tolerated 400
mg doses, children received 260 mg/m2. In general,
the early start of posttransplant IM administration
was well tolerated.
Hence, despite the different schedules regarding
indication, start, dosage, and duration of treatment,
most authors reported favorable tolerance of posttrans-
plant IM and successful resolution of serious adverse
events after dose reduction (Table 1). In all studies,
IM discontinuation because of toxicity was rare and
mostly temporary. However, close monitoring of
peripheral blood (PB) counts is strongly recommended
in patients receiving TKIs in the posttransplant period
as to perform dose reduction in time. Also, clinical
research should continue to evaluate the tolerance of
TKIs posttransplant given the myelotoxic comedica-
tions and the unstable hematopoiesis in this specific
situation.Duration of Treatment
According to the recent results of the STIM study
(‘‘Stop Imatinib Trial’’), 47% and 61% of (nontrans-
planted) patients had lost molecular CR 9 months
from discontinuation of IM with and without inter-
feron (IFN)-a treatment, respectively. Therefore, the
duration of IM therapy seems to be a sensible point,
probably especially for those who underwent allo-
SCT because of adverse risk profiles [15].
In most posttransplant studies, IM was continued
for periods from 9 to 14 months [7-9,11]. Palandri
et al. [11] continued IM for longer periods witha median treatment duration of 31 months. In total,
12 of 16 (75%) patients with either hematologic, cyto-
genetic, or molecular relapse of CP or AP/BP achieved
molecular CR. This suggests that prolonged treatment
with IM is effective and feasible in the posttransplant
period and can be safely administered over longer
periods.
Olavarria et al. [16] reported on a cohort of 22
patients who had all received reduced intensity condi-
tioning (RIC) in newly diagnosed or late first CP.Most
patients (82%) were minimal residual disease (MRD)-
positive before SCT. Following SCT, only 1 of 22
patients (5%) achieved molecular CR, whereas 95%
were still BCR-ABL-positive. IM was started on day
135 in all patients. When IM was stopped after 1
year of treatment, 95% of patients had achieved
a 3-log reduction in BCR-ABL transcripts; being
accompanied by molecular CR in 33% of those cases.
However, several months after discontinuation of IM
(median 6 months, range: 2-18 months), only 29% of
patients maintained molecular CR or at least stable
low-level molecular disease (BCR-ABL/ABL ratio:
#0.02%), whereas 71% patients had molecular
relapse. This demonstrates that interruption of post-
transplant IM is associated with high risk for disease
recurrence at least in patients who fail to achieve
molecular negativity following SCT.
On the other hand, long-term application of IM
has to be outbalanced with safety in the posttransplant
period [14]. Moreover, it remains to be seen whether
posttransplant IM alone is sufficient to guarantee con-
tinued molecular CR in patients with a residual leuke-
mia cell load after SCT, or whether a combination
with donor lymphocytes is required [17].Immunomodulation by Posttransplant Imatinib
IM was shown to have immunomodulating activi-
ties in several studies [18]: first, the compound can
impair the differentiation of dendritic cells from either
CD341 peripheral blood progenitor cells (PBPCs) or
monocytes as suggested by the in vitro studies of Appel
et al. [19]. Moreover, these dendritic cells were unable
to elicit primary or secondary T cell responses. Taieb
et al. [20] confirmed these results in an animal model as
feeding of mice with IM resulted in the inhibition of
Flt3 ligand-induced expansion of dendritic cells and
impaired the induction of a protective antitumor im-
munity. The in vivo results of Boissel et al. [21] in
CML patients suggested that IM inhibits the normal
development of dendritic cells.
In addition to the inhibition of monocyte and
macrophage development [22], IM was shown to ham-
per T cell proliferation. An in vitro study from
Cwynarsky et al. [23] demonstrated that IM inhibits
the proliferation and activation of T cells at concentra-
tions representative of the pharmacologic doses used
Table 1. Posttransplant Use of First- or Second-Generation TKIs in Patients with BCR-ABL-Positive Diseases
Reference No. of pts Compound
Indication to
posttranspl. TKIs
Med. start of TKIs
from SCT
(months)
Med. Treatment
Duration
(Months)
Toxicity (Grade)
Dose Red./
Interruption
Acute GVHD
(Grade)
Outcomes of
{osttransp. TKI
TreatmentHematologic Hepatic Other
Carpenter et al.
[10]
22 Imatinib Prophylaxis 28 days (range :
21-39 days)
12 NeutroY
(II-III): 2/22
ThromboY
(II-III): 2/22
6/22 (I-III) 12/22 (I-III) 13 — CCgR: 13/15 ALL;
5/7 CML; PCR
neg. : 12/15
ALL; 5/7 CML
Relapse: 2/7
CML
Hess et al. [14] 44 Imatinib Relapse
(CyR, MR)
2 months 8 NeutroY
(III-IV): 6/44
ThromboY
(I-II): 2/44
n.a. 20/44 (I-II) 5 — CCgR: 11/15
CMR: 23/37
MMR: 6/37
SMR: 8/37
Median
time to CMR:
3.3 months
Kantarjian et al.
[7]
28 Imatinib Relapse (HemR,
CyR, MR)
41 (range : 3-140) 11 NeutroY: 6/14
Thrombo Y: 4/15
5/28 9/28 (III-IV) 11 1/28 (II); 3/28 (III) CHR: 17/23
CCgR: 9/26
PCgR: 6/26 1-
year OS:
(n520) 74%
DeAngelo
et al. [8]
15 Imatinib Relapse
(HemR, CyR)
31 (range : 0.5-72) 14 1/15 3/15 — 3 1 (II-IV) CHR: 11/15
CCgR: 11/15
PCR neg.: 7/15
1-year OS in
CP: (n 5 10)
100%; OS in
AP/BP: 1/5 alive
Palandri et al. [11] 16 Imatinib Relapse (HemR,
CyR, MR)
54 (range: 7-160) 31 NeutroY
(III): 4/16
ThromboY
(III) : 1/16
— 2/16 (II) 7 — CCgR: 14/16 at
4.6 months
PCR neg.: 12/
16 at 30
months
Olavarria et al. [9] 128 Imatinib Relapse (HemR) 14 (range : 1-161) 9 Severe
pancytopenia:
6/128
n.a. n.a. 6 cGvHD re-
exacer- bation:
3/27
CHR: 71% CCgR:
42%; 2-year
OS: Overall (n
5 86) 65%; CP:
(n 5 51) 100%;
AP: (n 5 25)
86%; BP: (n 5
10) 12%
Olavarria et al.
[16]
22 Imatinib Prophylaxis 35 days 12 n.a. n.a. n.a. 3 — Relapse: 15/22
(68%) at
a median
of 6 months
(2-18) from IM
stop; 3-year-
OS: (n 5 19)
87%; mol.
remission after
DLI: 15/22
(68%)
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Biol Blood Marrow Transplant 16:301-310, 2010 305Tyrosine Kindas Inhibitor Treatment for Patients with CMLtherapeutically in vivo. This effect is reversible,
antigen-presenting cells independent, and does not
involve induction of apoptosis. Further, Leder et al.
[24] demonstrated that IM inhibits antigen-specific
IFN-gamma secretion of both CD41 and CD81 T-
effector cells at therapeutically relevant concentra-
tions, whereas T cells remain responsive and the
effector T cells are modulated rather than suppressed.
In a murine model, IM had immunosuppressive effects
by inhibiting antigen presentation and T cell effector
functions [25]. Therefore, the treatment of patients
with higher doses of IM could result in a more
profound suppression of CD8 T cells [26,27]. More-
over, treatment of patients with IM could influence
the graft-versus-leukemia (GVL) effect of lympho-
cytes (including CD81 T cells) in allo-SCT, and also
lead to increased susceptibility to infections with
viruses and other pathogens [14,28-31]. The in vivo
study from Sinai et al. [32] showed that IM diminishes
the recall response of specific CD81 T cells to patho-
gen exposure and could therefore affect the ability of
CD81 T cells to function optimally against relapsed
tumors or other infections. On the other hand, in the
study from Bocchia et al. [33,34] in 16 CML patients
who received prolonged treatment (.12 months)
with imatinib after immunization with weakly immu-
nogenic p210-derived peptide antigens as immuno-
logic adjuvants, imatinib did not seem to impair
specific antileukemic T cell immunity. At the present
time it has not been documented whether the immu-
nosuppression caused by posttransplant IM could
increase the relapse risk in CML patients. Moreover,
there was a trend to lower relapse rates patients who
received either pre- or posttransplant IM compared
with those who did not (13% versus 35%; P 5 .2),
respectively [35].
It remains important to evaluate whether post-
transplant IM modifies the probability of acute or
chronic graft-versus-host disease (aGVHD, cGVHD).
A recent report suggested that IM inhibits
(CD41CD251) regulatory T cells, therefore reducing
peripheral immune tolerance [36]. However, Olavarria
et al. [9] reported no case of de novo GVHD in a total
of 30 patients with IM in the posttransplant period.
Reactivation of aGVHD or cGVHD was observed in
3 patients, but probably without any association to
TKIs. Other series either had no case of de novo
GVHD or saw no exacerbation of already existing dis-
ease in stem cell recipients under IM [7,8,10,11]. In
some cases, successful use of IM for refractory sclero-
dermous cGVHD has been reported [37]. To our
knowledge, no studies so far compared the frequencies
of aGVHD or cGVHD in the content of posttrans-
plant IM. Concerning calcineurin inhibitor serum
levels, these seem not be affected by IM as being dem-
onstrated in 19 stem cell recipients under cyclosporine
or tacrolimus regimens [10].
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Period
Resistance against IM is categorized in BCR-ABL-
dependent or BCR-ABL-independent mechanisms.
BCR-ABL-dependent mechanisms are thought to be
the most common reason for the development of ac-
quired IM resistance and aremostly associated to point
mutations in the ABL kinase domain [38]. Mutations
conferring IM resistance are associated with advanced
disease, presence of cytogenetic clonal evolution, or
failure to achieve a cytogenetic CR after 12 months
of IM [39,40]. Whereas IM-resistance conferring mu-
tations were described in\15% of patients in CP, they
were found in 60% of patients in AP and 90% of those
in BP within 3 years of therapy [41]. Therefore, pa-
tients who are selected for allo-SCT will frequently
have a history of IM resistance. This emphasizes the
need for alternative strategies for part of CML patients
in the posttransplant period.
With respect to second-generation TKIs, the mul-
tikinase inhibitor dasatinib has been approved for the
treatment of IM-resistant and -intolerant patients
across all phases of CML and Phi1 ALL [42]. Dasati-
nib was shown to confer higher in vitro activity against
native BCR-ABL and to be active against all IM-
resistant BCR-ABL mutations with the exception of
T315I [43]. Nilotinib was recently approved by the
FDA for patients with CP or AP CML being resistant
to or intolerant of IM or other prior therapy, and is
also effective against all IM-resistantABL kinasemuta-
tions except T315I [44]. Thus, there seems to be no
adequate solution for patients with a T315I mutation.
In this setting the development of newTKIs appears to
be crucial [45].
So far, reports describing the role of second-gener-
ation TKIs as an early posttransplantation strategy are
very limited. In an own series, 9 patients with advanced
phases of CML received dasatinib in the posttrans-
plant period [13]. Interruption of dasatinib was
necessary in 1 case only (13%) because of thrombocy-
topenia-related gastrointestinal bleeding. Atallah et al.
[12] analyzed outcomes in another 11 stem cell recip-
ients with CML or Phi1ALL, who received treatment
with dasatinib and reported as well favorable tolerance
of the compound in the posttransplant period.
Although there were rather high rates of gastrointesti-
nal (GI) bleeding (27%), pulmonary complications
(18% of patients), or liver toxicity (being seen in
9%), side effects were well manageable in most cases
by dose reduction or interruption of treatment.
Considering the efficacy of second-generation
TKIs, the number of patients receiving these
compounds in the posttransplant period is too limited
for definite conclusions. Results have to be seen on
the background of adverse risk profiles of patients being
so far reported. Atallah et al. [12] achieved transientmajor molecular CR in 3 of 11 patients with chronic
or advanced phase of CML or with Phi1 ALL. In an
own series, stable response to posttransplant dasatinib
was seen in 4 of 9 CML patients who all had a history
of AP/BP or extramedullary disease [13].
In contrast to IM, which appears to be unable to
penetrate the extramedullary tissue [46] or the central
nervous system [47,48], dasatinib may be useful for
posttransplant extramedullary relapse of CML [49].
In the conservative treatment setting, response to dasa-
tinib was reported in 79% of patients with CNS
involvement and IM resistant Phi1 disorders [50].
In conclusion, first reports suggest that dasatinib
can be administered with acceptable tolerance in the
posttransplant period. Considering the limited
amount of data, second-generation TKIs should be
further evaluated for use in the posttransplant period
in patients with a history of IM resistance/intolerance
or advanced stages of CML.Monitoring Strategies during Posttransplant
TKI Treatment
The use of diagnostic methods has not been stan-
dardized for the posttransplant period of CML in con-
trast to the monitoring of nontransplanted patients
under IM treatment [51-53]. With quantitative real-
time PCR, a highly sensitive tool is available for the
determination of the molecular response, and criteria
for the definition of molecular and cytogenetic
response to IM were internationally standardized
[51-54]. Within the conservative therapy setting, kar-
yotyping was suggested to be repeated at least every
6 months until cytogenetic CR has been achieved,
then every 12 months. Quantitative PCR was pro-
posed to be performed every 3 months, even after
achievement of molecular negativity [53].
In contrast, it is still difficult to determine the
meaning of positive results in the posttransplant
period. Kaeda et al. [55] performed serial BCR-ABL
measurement in 243CML patients to define themean-
ing of low BCR-ABL transcript levels frequently being
identified in the posttransplant period in patients with
CML. The authors subdivided patients according to
their posttransplant BCR-ABL expression status in
the following categories: ‘‘persistently negative’’;
‘‘fluctuating positive, low level’’ (.1 positive result
but never .2 consecutive positive results); ‘‘persis-
tently positive, low level’’ (persisting BCR-ABL/ABL
transcripts#0.02%, but never$3 consecutive positive
results), and ‘‘molecular relapse’’ (3 positive results
with a BCR-ABL/ABL ratio $0.02% or 2 results
.0.05% over $4 weeks). In this series, only patients
who fulfilled the criteria of molecular relapse were
likely to progress, whereas those who had fluctuating
low BCR-ABL levels had no increased relapse risk [55].
Biol Blood Marrow Transplant 16:301-310, 2010 307Tyrosine Kindas Inhibitor Treatment for Patients with CMLCombination of TKIs with Adoptive
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Since being first reported in 1990,DLIs weremain-
stay of treatment for relapsing CML [56,57] as stable
responses were achieved in 60%–70% of patients with
recurrence of CP [57-60], whereas durable CRs were
less frequent in patients relapsing into AP/BP.
There are few reports regarding the combinationof
IM with DLI. In the study from Kantarjian et al. [7],
DLIs were given to 13 of 28 patients with relapse of
advanced CML. The median interval between DLI
and IM was 4 months (range: 3-29 months). Although
this regimen was well tolerated, there were no differ-
ences inCR rates compared to the cohort of 15 patients
who received noDLI. DeAngelo et al. [8] administered
DLI.12months before start of posttransplant IM in 4
of 15 patients with different phases of CML. There
were no signs of increased toxicity of this combined
approach, and 2 patients achieved a transient cytoge-
netic CR. Most authors reported the use of DLI in
IM-treated patients with intervals of 4 to 12 months
from stop of posttransplant IM treatment [7,8,11].
Weisser et al. [61] compared use of IM and DLI in
CML relapse. The majority of patients from the 2
groups were in cytogenetic relapse (n 5 23), whereas
8 patients were in hematologic relapse. IM was admin-
istered at a dose of 400-800 mg/day depending on
response. There was a significantly lower relapse rate
(14% versus 60%) and improved disease-free survival
(DFS) in the DLI compared to the IM group. Savani
et al. [17] performed comparison of 3 groups of pa-
tients with hematologic or molecular relapse of
CML, who received either IM, DLI, or a combination
of both in concurrent or sequential regimens. DLIs
were given in incremental doses from 1  107 to 10
 107 CD31 cells/kg every 3 months or faster in case
of progression. The authors observed a beneficial ef-
fect of the DLI/IM combination compared to the use
of either agent alone: with the combination, patients
were able to stop IM without recurrence of molecular
disease and had a superior overall (100%, 89%, and
54% for IM/DLI, IM, and DLI, respectively; P 5
.02) and DFS after treatment (100%, 54%, and 43%
for IM/DLI, IM, and DLI; P 5 .03). It was also re-
markable that molecular CR was sooner achieved in
patients receiving the DLI/IM combination compared
to DLI or IM alone (90%, 7.7%, and 11% at 3 months
from start of treatment). Considering AP CML, all 4
patients achieved molecular remission and are cur-
rently disease free after follow-ups of 8-42 months.
There are abundant data indicating that IM can re-
duce the disease bulk in CML, but little evidence that
leukemic progenitors are permanently eliminated,
because disease recurrence typically follows with-
drawal of IM. In contrast, DLI is believed to exert an
immune-mediated GVL effect [62], which canpermanently eliminate residual disease. The combina-
tion of DLI and IM is therefore logical: IMmay reduce
disease burden readily to levels below molecular
detection, but alone it is incapable of preventing
recurrence. However, further prospective studies are
required to evaluate a benefit of such combination.CONCLUSIONS
Although the number of studies and the number of
investigated patients concerning the posttransplant
use of TKIs are limited [7-9,11], some conclusions
can already be drawn.
The application of either first- or second-genera-
tionTKIs showed adequate efficacy and acceptable tol-
erance in patients with CML after allo-SCT [9,12,13].
There seems to be a tendency for better outcome in
case of cytogenetic and molecular relapses when com-
pared to hematologic relapse [14]. Furthermore, use
of these compounds as preventive strategy in either
all or selected groups of patients in the posttransplant
period seems feasible [10]. Such strategy could also
contribute to an appropriate timing for DLI and other
immunotherapeutic interventions [16].
The time point of start of TKI treatment does not
seem to be very critical. Early administration of imati-
nib even within the first months after allo-SCT seems
to be feasible [10]. Although in some studies IM dos-
ages were higher than recommended for standard reg-
imens, adverse event rates were not increased [7].
Moreover, posttransplant TKI treatment seemed to
be feasible despite the different comedications, which
are standard in the posttransplant period. Concerning
the duration of posttransplant TKIs therapy, it is
important to note, that long-term application (.1
year) should be more preferable when compared to
short-term application (\1 year) [16]. It is not clear,
whether life-long therapy duration would be associ-
ated with better outcomes.
However, it should be mentioned again that
additional data will be needed to evaluate the efficacy
and tolerance of posttransplant imatinib for patients
with CML considering the limited number of studies
and the limited follow-up period since the introduction
of imatinib in prophylaxis and treatment of stem cell
recipients with CML. Another important issue is the
apparent immunomodulating potential of imatinib.
However, the clinical impact of these immunomodula-
tory properties in the posttransplant periodremains
unclear [24,25,36]. As pretransplant strategy, IM was
associated to a reduction of cGVHD rates. Whether
the posttransplant application of IM has the same
effect, is uncertain [63,64].
Further, it has to be seen that many patients being
selected for allo-SCT today have had a history of
308 Biol Blood Marrow Transplant 16:301-310, 2010E. Klyuchnikov et al.resistance to imatinib. Thus, the most appropriate
strategies for these patients are still difficult to define.
One option might be represented by a second genera-
tion of TKIs. However, at present times, there are no
large studies, although existing data suggests that these
compounds might represent a therapeutic alternative
for patients with IM failure or extramedullary relapses
[46-49]. Concerning patients with resistance to imati-
nib and second-generation TKIs, for example, because
of the T315I mutation, novel TKIs should be explored
for use in the posttransplant period. Small molecule
inhibitors simultaneously targeting Aurora kinases
and BCR-ABL kinases might represent a promising
approach [65].
The combination of IM with DLI seems to be fea-
sible and well tolerated, but whether this combination
is more efficient than IM alone remains to be further
clarified. Regarding the relapse rate, there is a tendency
to decreased relapse incidence in case of using IM to-
gether with DLI [17,61]. Nevertheless, the question
whether this approach is associated with improved sur-
vival rates when compared to IM alone remains open at
this time, which applies as well to the best appropriate
combination strategies of posttransplant TKIs and
DLIs. Thus, a standardization of the posttransplant
application of TKIs—regarding intervals from SCT,
dosages, treatment duration, and the combination
with DLIs—is urgently needed. Multicenter studies
should focus on this aspect aiming to improve out-
comes of the high risk patients with CML being
selected for allo-SCT.ACKNOWLEDGMENTS
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